the Company: For more information, click here: http://zlk.9nl.com/pdl-biopharma-pdli , according to Market Watch. On August 8, 2014, the Company announced it would require an extension for the filing of its Quarterly Report on Form 10-Q for the period ended June 30, 2014. On September 16, 2014 the Company filed a Form 8-K with the SEC announcing that its independently registered accounting firm, Ernst Young, was resigning and Levi Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Nevada on behalf of investors who purchased PDL BioPharma Inc. "PDL" or the "Company" -0.92% common stock between November 6, 2013 and September 16, 2014. The complaint alleges that PDL issued materially false and/or misleading statements regarding the Company business, operations, prospects, and performance. In particular, it is alleged that the Company made false and/or misleading statements and/or failed to disclose that it was overstating its a total revenues; b royalty revenues; c net income; and d net cash provided by operating activities. The complaint further alleges that the Company failed to properly classify royalty and milestone payments due under an agreement with Depomed.
(news.financializer.com). As
reported in the news.
Tagged under , Ernst Young topics.